# US 10,307,405 B2 · Stable veterinary combination formulations of macrocyclic lactones and imidazothiazoles > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,307,405 B2 - Document ID: US10307405B2 - Status: Granted - Kind: B2 - Application number: 14/779,045 - Filed: 2014-04-10 - Published: 2016-02-25 - Granted: 2019-06-04 - Earliest claimed: 2013-04-12 - Assignees: Zoetis Services LLC - Applicants: Zoetis Services LLC - Inventors: Guy Francis de Rose; Sachin Pundlik Kolhe - Web page: https://patentgrep.com/patent/US10307405B2 ## CPC - A61K 31/429: condensed with heterocyclic ring systems - A61K 9/0017: {Non-human animal skin, e.g. pour-on, spot-on} - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 31/365: Lactones - A61K 31/415: 1,2-Diazoles - A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles - A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} - A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61P 33/00: Antiparasitic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention is directed to stabilized compositions comprising at least one macrocyclic lactone, or derivative thereof, in combination with levamisole, and an amino sugar stabilizing agent, optionally an additional antiparasitic agent, and a method for treating or controlling a parasitic infection or infestation in an animal by administering said composition. ## Claims ### Claim 1 A stable injectable veterinary antiparasitic composition comprising: (a) a therapeutically effective amount of doramectin, wherein the doramectin is present in the composition in the amount of about 0.1% w/w to about 1% w/w; (b) a therapeutically effective amount of levamisole, or a pharmaceutically or veterinarily acceptable salt thereof, wherein the levamisole is present in the composition in the amount of about 4% w/w to about 24% w/w; (c) an amino sugar stability enhancer consisting of meglumine; and (d) at least one pharmaceutically or veterinarily acceptable carrier selected from the group consisting of benzyl alcohol, glycerol formal, triethylene glycol, and mixture thereof, and further comprising butylated hydroxyanisole, butylated hydroxytoluene, or mixture thereof. ### Claim 2 (depends on 1) The composition of claim 1, wherein the meglumine is present in the composition in the amount of about 0.01% w/w to about 0.2% w/w. ### Claim 3 (depends on 1) The composition of claim 1, wherein the levamisole is levamisole hydrochloride. ### Claim 4 (depends on 1) The composition of claim 1 wherein the at least one pharmaceutically or veterinarily acceptable carrier is selected from benzyl alcohol, triethylene glycol, or mixture thereof. ### Claim 5 (depends on 1) The composition of claim 1 wherein the at least one pharmaceutically or veterinarily acceptable carrier is glycerol formal. ### Claim 6 A stable injectable veterinary antiparasitic composition comprising: (a) a therapeutically effective amount of doramectin present in the composition in the amount of about 0.1% w/w to about 1% w/w; (b) a therapeutically effective amount of levamisole, or a pharmaceutically acceptable salt thereof, present in the composition in the amount of about 4.0% w/w to about 24% w/w; (c) an amino sugar stability enhancer consisting of meglumine, present in the composition in the amount of about 0.01% w/w to about 0.2% w/w; and (d) at least one pharmaceutically or veterinarily acceptable carrier selected from the group consisting of benzyl alcohol, glycerol formal, triethylene glycol, and mixture thereof, and further comprising butylated hydroxyanisole, butylated hydroxytoluene, or mixture thereof. ### Claim 7 (depends on 6) The composition of claim 6 wherein the at least one pharmaceutically acceptable carrier is selected from benzyl alcohol, triethylene glycol, or mixture thereof. ### Claim 8 (depends on 6) The composition of claim 6 wherein the at least one pharmaceutically or veterinarily acceptable carrier is glycerol formal. ### Claim 9 A method for alleviating a parasitic infection in an animal, comprising administering to said animal in need thereof, a stable injectable composition comprising: (a) a therapeutically effective amount of doramectin present in the composition in the amount of about 0.1% w/w to about 1% w/w; (b) a therapeutically effective amount of levamisole, or a pharmaceutically acceptable salt thereof, present in the composition in the amount of about 4.0% w/w to about 24% w/w; (c) an amino sugar stability enhancer consisting of meglumine; and (d) at least one pharmaceutically or veterinarily acceptable carrier selected from the group consisting of benzyl alcohol, triethylene glycol, glycerol formal, and mixture thereof, and further comprising butylated hydroxyanisole, butylated hydroxytoluene, or mixture thereof. ### Claim 10 (depends on 9) The method of claim 9 wherein the meglumine is present in the composition in the amount of about 0.01% w/w to about 0.2% w/w. ### Claim 11 (depends on 10) The method of claim 10 wherein the at least one pharmaceutically or veterinarily acceptable carrier is selected from benzyl alcohol, triethylene glycol, or mixture thereof. ### Claim 12 (depends on 10) The method of claim 10 wherein the at least one pharmaceutically or veterinarily acceptable carrier is glycerol formal. ### Claim 13 (depends on 9) The method of claim 9 wherein the animal is cattle or sheep. ### Claim 14 (depends on 9) The method of claim 9 wherein the composition is administered to the animal by subcutaneous injection.